Make an Inquiry

    Sorry, We are 100% Exporting company, We are not selling in India.

    Multiple Electrolyte ‘M’ And Dextrose Injection


    Multiple Electrolyte ‘M’ And Dextrose Injection


    250ml / 500ml / 1000ml



    Production Capacity

    1 Million Injection/Month

    Plasma-Lyte® M and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 2, USP) is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single dose container for intravenous administration. Each 100 mL contains 5 g Dextrose Hydrous, USP*, 161 mg Sodium Acetate Trihydrate, USP (C2H3NaO2•3H2O); 138 mg Sodium Lactate (C3H5NaO3), 119 mg Potassium Chloride, USP.

    Multiple Electrolytes and Dextrose Injection, Type 2, USP) administered intravenously has value as a source of water, electrolytes, and calories. One liter has an ionic concentration of 40 mEq sodium, 16 mEq potassium, 5 mEq calcium, 3 mEq magnesium, 40 mEq chloride, 12 mEq acetate, and 12 mEq lactate. The osmolarity is 377 mOsmol/L (calc). Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. Administration of substantially hypertonic solutions ( ≥ 600 mOsmol/L) may cause vein damage. The caloric content is 180 kcal/L.The Viaflex® plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146® Plastic).

    The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials.Multiple Electrolytes and Dextrose Injection, Type 2, USP) is indicated as a source of water, electrolytes, and calories or as an alkalinizing agent.Reactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation, and hypervolemia.

    If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary.


    Tages :